DEA proposed rules to make permanent telemedicine flexibilities used during COVID 19. Specifically, telemedicine prescribing of certain controlled substances without an in person medical examination and expansion of buprenorphine prescribing via telemedicine encounters.
On February 24, 2023, the federal Drug Enforcement Administration (DEA) issued a pair of proposed rules to make permanent certain “telemedicine flexibilities” related to the prescribing.